News

Aflibercept is an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF), currently being developed by New York-based Regeneron in collaboration with Sanofi-Aventis. These two trials will be double-blind

The cognitive deficits in schizophrenia (CDS) trial is a double blind, placebo-controlled study being conducted at sites in the US and Canada. The trial design provides for approximately

In addition, the trial showed a 71% reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5% in placebo group and 2.8 percent in

GPC Biotech withdrew satraplatin from the Fast Track approval process in the US after the FDA said that it would require overall survival data from a trial that

Angiogenesis inhibitors that block a tumor’s development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.

The company’s restructuring plan involves cutting 46 staff from a current total of 316 employees, or approximately 15% of the total workforce. All affected staff are based in

Exelixis confirmed that it has agreed to the request from GSK to initiate its review of XL880 before the compound reaches proof-of-concept. Exelixis expects to deliver the appropriate

In the extension phase of the study, 12 patients were treated at the highest dose, 480mg/m2/day, as determined in first portion of the trial. The phase I/II clinical

The preclinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with Onconase reduced intracellular oxidative stress